Zhe Xue

Zhe Xue


Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2022 in Chinese Medicine
Verified
Journal Article
Open access
PDF file
CLChenyue Liu
Chenyue Liu
JCJian-Bei Chen
Jian-Bei Chen
YLYue-Yun Liu
Yue-Yun Liu
XZXue-Ming Zhou
Xue-Ming Zhou
MZMan Zhang
Man Zhang
XLXiao-Juan Li
Xiao-Juan Li
Background: Many studies about depression have focused on the dysfunctional synaptic signaling in the hippocampus that drives the pathophysiology of depression. Radix Bupleuri has been used in China for over 2000 years to regulate liver-qi. Extracted from Radix Bupleuri, Saikosaponin D (SSD) is a pharmacologically active substance that has antidepressant effects. However, its underlying mechanism remains unknown. Materials and methods: A chronic unpredictable mild stress (CUMS) paradigm was used as a rat model of depression. SD rats were randomly assigned to a normal control (NC) group or one exposed to a CUMS paradigm. Of the latter group, rats were assigned to four subgroups: no treatment (CUMS), fluoxetine-treated (FLU), high-dose and low-dose SSD-treated (SSDH and SSDL). SSD was orally administrated of 1.50 mg/kg and 0.75 mg/kg/days for three weeks in the SSDH and SSDL groups, respectively. Fluoxetine was administrated at a dose of 2.0 mg/kg/days. SSD’s antidepressant effects were assessed using the open field test, forced swim test, and sucrose preference test. Glutamate levels were quantified by ELISA. Western blot and immunochemical analyses were conducted to quantify proteins in the Homer protein homolog 1 (Homer1)-metabotropic glutamate receptor 5 (mGluR5) and mammalian target of rapamycin (mTOR) pathways in the hippocampal CA1 region. To measure related gene expression, RT-qPCR was employed. Results: CUMS-exposed rats treated with SSD exhibited increases in food intake, body weight, and improvements in the time spent in the central are and total distance traveled in the OFT, and less pronounced pleasure-deprivation behaviors. SSD also decreased glutamate levels in CA1. In CA1 region of CUMS-exposed rats, SSD treatment increased mGluR5 expression while decreasing Homer1 expression. SSD also increased expressions of postsynaptic density protein 95 (PSD95) and synapsin I (SYP), and the ratios of p-mTOR/mTOR, p-p70S6k/p70S6k, and p-4E-BP1/4E-BP1 in the CA1 region in CUMS-exposed rats. Conclusions: SSD treatment reduces glutamate levels in the CA1 region and promotes the expression of the synaptic proteins PSD-95 and SYP via the regulation of the Homer1-mGluR5 and downstream mTOR signaling pathways. These findings suggest that SSD could act as a natural neuroprotective agent in the prevention of depression.

24 March 2022 in Frontiers in Pharmacology
Verified
Journal Article
Open access
QWQian Wu
Qian Wu
WDWen-Zhen Duan
Wen-Zhen Duan
JCJian-Bei Chen
Jian-Bei Chen
XZXiao-Peng Zhao
Xiao-Peng Zhao
XLXiao-Juan Li
Xiao-Juan Li
JCJiaxu Chen
Jiaxu Chen
Extracellular vesicles (EVs) are lipid bilayer-delimited particles released by cells, which play an essential role in intercellular communication by delivering cellular components including DNA, RNA, lipids, metabolites, cytoplasm, and cell surface proteins into recipient cells. EVs play a vital role in the pathogenesis of depression by transporting miRNA and effector molecules such as BDNF, IL34. Considering that some herbal therapies exhibit antidepressant effects, EVs might be a practical delivery approach for herbal medicine. Since EVs can cross the blood-brain barrier (BBB), one of the advantages of EV-mediated herbal drug delivery for treating depression with Chinese herbal medicine (CHM) is that EVs can transfer herbal medicine into the brain cells. This review focuses on discussing the roles of EVs in the pathophysiology of depression and outlines the emerging application of EVs in delivering CHM for the treatment of depression.

13 December 2013 in Trials
Verified
Journal Article
Open access
PDF file
ZXZhe Xue
Zhe Xue
CLCunzhi Liu
Cunzhi Liu
GSGuang-Xia Shi
Guang-Xia Shi
YLYan Liu
Yan Liu
ZLZhao-Xin Li
Zhao-Xin Li
LWLinpeng Wang
Linpeng Wang
Background Dizziness is one of the most challenging symptoms in medicine. No medication for dizziness in current use has well-established curative or prophylactic value or is suitable for long-term palliative use. Unconventional remedies, such as acupuncture, should be considered and scientifically evaluated. However, there has been relatively little evidence in randomized controlled clinical trials on acupuncture to treat chronic dizziness. The aim of our study is to evaluate the efficacy and safety of acupuncture in patients with dizziness. Methods/Design This trial is a randomized, single-blind, controlled study. A total of 80 participants will be randomly assigned to two treatment groups receiving acupuncture and sham acupuncture treatment, respectively, for 4 weeks. The primary outcome measures are the Dizziness Handicap Inventory (DHI) and the Vertigo Symptom Scale (VSS). Treatment will be conducted over a period of 4 weeks, at a frequency of two sessions per week. The assessment is at baseline (before treatment initiation), 4 weeks after the first acupuncture session, and 8 weeks after the first acupuncture session. Discussion The results from this study will provide clinical evidence on the efficacy and safety of acupuncture in patients with chronic dizziness. Trial registration International Standard Randomized Controlled Trial Number Register: ISRCTN52695239

30 April 2023 in Phytomedicine
Verified
Journal Article
Closed access
SLSiqi Liu
Siqi Liu
PDPengmin Ding
Pengmin Ding
MWMengjiao Wu
Mengjiao Wu
ZZZhihao Zhu
Zhihao Zhu
JTJiayue Tao
Jiayue Tao
RWRufeng Wang
Rufeng Wang

8 January 2022 in Archives of Microbiology
Verified
Journal Article
Closed access
PDF file
YPYuesheng Pang
Yuesheng Pang
SWSha Wang
Sha Wang
JTJiayue Tao
Jiayue Tao
JWJing Wang
Jing Wang
ZXZhe Xue
Zhe Xue
RWRufeng Wang
Rufeng Wang